ABI-6250's NTCP-targeting mechanism enters Phase 2 in HDV and cholestatic diseases; thesis hinges on whether early efficacy signals emerge across these indications

Bull

Phase 2 initiates on schedule in Q4 2026 with a well-designed protocol that incorporates meaningful efficacy endpoints such as HDV RNA suppression and ALT normalization, validating the NTCP mechanism in a clinically relevant setting. This would de-risk the broader NTCP platform thesis, lend credibility to the parallel PBC/PSC basket study, and position ABI-6250 as a differentiated oral entry-inhibitor in a space dominated by injectable agents, potentially attracting partnership interest.

Bear

Study initiation could be delayed by regulatory feedback, patient enrollment challenges in this rare orphan population, or dose-limiting findings that require protocol revision following chronic toxicology review. Even if initiated, early futility signals — such as insufficient HDV RNA reduction compared to bulevirtide benchmarks — would call into question whether NTCP inhibition alone is adequate in a disease requiring potent viral suppression.